Takagi, Erina
Terakura, Seitaro http://orcid.org/0000-0002-1194-8046
Fujigaki, Hidetsugu
Okamoto, Akinao
Miyao, Kotaro
Sawa, Masashi
Morishita, Takanobu
Goto, Tatsunori
Ozawa, Yukiyasu
Nishida, Tetsuya
Fukushima, Nobuaki
Ozeki, Kazutaka
Hanajiri, Ryo
Saito, Kuniaki
Murata, Makoto
Tomita, Akihiro
Kiyoi, Hitoshi
Funding for this research was provided by:
Japan Society for the Promotion of Science (JSPS) KAKENHI (22k08501)
Article History
Received: 17 March 2023
Revised: 24 July 2023
Accepted: 25 July 2023
First Online: 10 August 2023
Declarations
:
: H.F. and K.S. belong to an endowed department sponsored by FUJIFILIM Wako Pure Chemical Corporation. H.F. received a lecture fee from FUJIFILM Wako Pure Chemical Corporation. K.S. received research funding from FUJIFILM Wako Chemical Corporation. A.T. received research funding from Chugai Pharmaceutical, Astellas Pharma, Eisai, Otsuka Pharmaceutical, Ono Pharmaceutical, Kyowa Kirin, Shionogi, Sumitomo Dainippon Pharma, Taiho Pharmaceutical, Takeda Pharmaceutical, Teijin, Nippon Shinyaku, Nihon Pharmaceutical, Pfizer Japan, Mochida Pharmaceutical, Yakult Honsha, and Perseus Proteomics; and lecture fees from Chugai Pharmaceutical, Kyowa Kirin, Eisai, Takeda Pharmaceutical, Astellas Pharma, Nippon Shinyaku, Janssen Pharmaceutical, Zenyaku Kogyo, Abbvie GK, Bristol Myers Squibb, and SymBio Pharmaceutical. H. Kiyoi received research funding from FUJIFILM, Kyowa Kirin, Bristol Myers Squibb, Otsuka, Perseus Proteomics, Daiichi Sankyo, Abbvie, CURED, Astellas Pharma, Chugai, Zenyaku Kogyo, Nippon Shinyaku, Eisai, Takeda, Sumitomo Pharma, and Sanofi, and honoraria from Abbvie, Chugai, Astellas Pharma, and Novartis. The other authors declare no competing financial interests.